The Zhitong Finance App learned that UBS released a research report saying that Yao Ming Biotech (02269.HK) reached an exclusive cooperation agreement with German medical company Fresenius to obtain developer ET rights for 37 biosimilar drugs within the next ten years. This move is seen as an affirmation of the company's R&D strength, maintaining a “buy” rating, and the target price is HK$62.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.